High-dose_chemotherapy_with_reinfusion_of_purged_autologous_bone_marrow_following_dose-intense_induction_as_initial_therapy_for_metastatic_breast_cancer._We_assessed_the_toxicity_and_efficacy_of_high-dose_chemotherapy_consolidation_with_reinfusion_of_purged_autologous_bone_marrow_in_women_with_metastatic_breast_cancer_responding_to_a_dose-intense_outpatient_regimen._Thirty_women_with_hormone-unresponsive_metastatic_breast_cancer,_previously_untreated_with_adjuvant_doxorubicin_or_with_any_chemotherapy_for_metastatic_disease,_were_treated_with_cyclophosphamide,_methotrexate,_doxorubicin,_fluorouracil,_vincristine,_and_leucovorin_for_16_weeks._Twenty-four_patients_responded_to_therapy;_8_showed_a_complete_response,_and_16_showed_a_partial_response._These_patients_proceeded_to_the_next_phase_of_the_protocol,_ie,_marrow_harvest_and_treatment_with_6000_mg/m2_cyclophosphamide_and_800_mg/m2_thiotepa_given_over_4_days._Harvested_marrow_was_purged_with_100_micrograms/mL_4-hydroperoxycyclophosphamide,_and_all_patients_engrafted_satisfactorily._The_predominant_side_effects_were_myelosuppressive_and_gastrointestinal,_and_there_were_no_deaths_from_toxic_effects._Three_of_the_16_patients_who_showed_a_partial_response_after_the_outpatient_phase_of_treatment_achieved_a_complete_response_after_high-dose_therapy._The_partial_response_seen_in_two_more_patients_converted_to_a_complete_response_at_all_sites_except_bone._The_median_time_to_disease_progression_for_all_patients_in_this_study_was_13_months,_and_the_median_survival_was_22_months._Four_of_the_original_30_patients_remained_without_disease_progression_a_median_of_27_months_from_entry_into_the_study._This_study_indicates_that_this_dose-intense_regimen_can_be_safely_administered,_even_with_the_use_of_purged_marrow,_with_an_acceptable_toxicity_profile._This_approach_results_in_a_high_response_rate_in_women_with_metastatic_breast_cancer_and_could_form_the_basis_for_a_regimen_to_be_tested_in_the_high-risk_adjuvant_setting.